Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 7, 2009

Vernalis and Servier Sign Second Cancer Drug Discovery Agreement

  • Vernalis and Servier signed a three-year collaboration to harness Vernalis’ fragment- and structure-based drug discovery platform for the identification of drug candidates against a new cancer target.

    The deal is in addition to the companies’ existing collaboration, signed in May 2007, focused on two oncology targets involved in protein-protein interactions. In October 2008, Vernalis received a €500,000 milestone from Servier for solving the novel crystal structure of one of the targets.



Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »